Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.54M | $-6.54M | $-0.98 |
| 2024 | $8.27M | $-3.30M | $-1.11 |
| 2023 | $11.85M | $3.03M | $472.50 |
| 2022 | $10.69M | $-5.43M | $-2920.50 |
| 2021 | $9.88M | $666.3K | $3282.75 |
Social Signal Score
Valuation
CDIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsaccessnewswire.com·3d ago·Neutral
Cardiff Lexington Announces Second Quarter 2026 Financial Results LEXINGTON, KY / ACCESS Newswire / August 12, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commen
View source ↗
